2017 American Society of Hematology Annual Meeting*

December 9-12, 2017; Atlanta, Georgia
Shaji Kumar, MD, and Sagar Lonial, MD, review and share their expert perspectives on key findings in multiple myeloma presented at the 2017 ASH annual meeting.
Shaji Kumar, MD
Sagar Lonial, MD

Multiple Myeloma

This prospective subanalysis of the phase III EMN02/HO95 trial suggests benefit in PFS and OS with double ASCT, particularly for patients with high-risk MM.

Released: December 14, 2017

The use of KRd induction plus transplantation and consolidation resulted in a CR or better in approximately 75% of patients with high-risk smoldering myeloma with an acceptable safety profile.

Released: December 12, 2017

BCMA-CART with or without cyclophosphamide lymphodepletion demonstrates promising clinical activity in heavily pretreated patients with MM.

Released: December 12, 2017

Combined infusion of CD19- and BCMA-specific CAR T-cells generally well tolerated and produces high remission rates in patients with relapsed/refractory multiple myeloma.

Released: December 14, 2017

Daratumumab monotherapy demonstrated clinical activity and a favorable safety profile in patients with intermediate- and high-risk smoldering multiple myeloma.

Released: December 15, 2017

Extended follow-up continues to demonstrate significant increase in PFS with addition of daratumumab to lenalidomide/dexamethasone for patients with relapsed/refractory myeloma.

Released: December 19, 2017

Results from the dose escalation show that second-generation bb2121 CAR T-cell therapy yielded a 94% ORR and a 56% CR rate in heavily pretreated patients with relapsed/refractory MM.

Released: December 14, 2017

A new human scFv-derived BCMA-targeted CAR T-cell appears tolerable with no reported dose-limiting toxicity and preliminary evidence of activity in patients with heavily pretreated myeloma.

Released: December 15, 2017

In evaluable patients who relapsed following initial RVD therapy (with or without upfront ASCT), 4 cycles of PCD yielded an ORR of 85% with 95% of transplant-naive patients proceeding to a first ASCT.

Released: December 12, 2017

The use of manual subcutaneous injection of coformulation of daratumumab and rHuPH20 enabled short administration, was well tolerated, and demonstrated a response rate similar to IV daratumumab.

Released: December 15, 2017

Use of elotuzumab/lenalidomide/dexamethasone maintenance therapy following autologous stem cell transplantation in patients with multiple myeloma improved quality of response in 36% of patients in this preliminary analysis.

Released: December 18, 2017

Among patients with newly diagnosed MM not undergoing ASCT, ixazomib-based induction followed by ixazomib maintenance therapy was associated with an ORR of 94%, including a CR rate of 35%.

Released: December 18, 2017

In this online course, Shaji Kumar, MD, and Sagar Lonial, MD, discuss the results and provide their perspective on the clinical applicability of key multiple myeloma studies presented at the Hematology 2017 annual meeting.

Shaji Kumar, MD Sagar Lonial, MD Physicians: maximum of 3.0 AMA PRA Category 1 Credits Released: March 14, 2018 Expiration: March 13, 2019

The combination of daratumumab plus VMP reduced the risk of progression or death by 50% vs VMP alone in transplantation-ineligible patients with newly diagnosed myeloma in this randomized, open-label phase III study.

Released: December 13, 2017
Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC

Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Dr
Dinah Shore Bldg.
Rancho Mirage, CA 92270

Alma Perez, Accreditation Specialist
(760) 773-4506
(760) 773-4550 (Fax)
ce@annenberg.net
http://www.annenberg.net/

This activity is supported by educational grants from
AbbVie
AstraZeneca
Celgene Corporation
Genentech
Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
Jazz Pharmaceuticals
Novartis Pharmaceuticals Corporation
Pharmacyclics Inc.
Seattle Genetics
Takeda Oncology

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?